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A Place for Radiofrequency Ablation in the Treatment
of Resectable Colorectal Liver Metastases?
To the Editor:
With great interest we read the exhaustive review
‘‘Radiofrequency Ablation versus Resection for Resectable
Colorectal Liver Metastases: Time for a Randomized
Trial?’’1 in which Mulier et al. clearly summarizes the litera-
ture regarding radiofrequency ablation (RFA) as a treatment
option for colorectal liver metastases (CRLM). The authors
propose arguments and criteria for a noninferiority trial
comparing RFA and resection for resectable CRLM with 5-
year survival as a main outcome. However, we believe that
they compare apples and oranges in their review of literature.
In accordance with the Editorial by Curley,2 we do not think
it is time for a randomized trial for resectable lesions yet.
There is the main problem of defining the effectiveness of
the technique. We agree with their statement that RFA
should only be attempted when complete eradication of the
tumor including a safety margin is possible, but review of the
available data is debatable as different definitions of tech-
nique effectiveness are being used.3 How should we manage
lesions being treatedwithRFA that showhypervascularity at
the periphery in follow-up? Should we perform a second
RFA treatment, or a resection as rescue therapy? One has to
study the outcome of incompletely RFA treated lesions that
necessitate additional intervention either byRFAor surgery.
Patients should be well informed that they might need a
second intervention after initial treatment failure. As results
from pathologic examination of larger series are currently
lacking, well-defined local failure (incompletely ablated tu-
mor tissue that continues to grow) and local recurrence rates
(new tumor foci growing at the original ablated site)4 and
their outcome remain to be established before RFA can
challenge resection in a randomized trial.
In the proposed trial, the authors suggest a surgical RFA
approach. According to our results and those of others, the
surgical approach appears to be superior to the percutane-
ous route in achieving local control,4 and it is clear that the
open approach offers the advantage of direct examination
for extrahepatic intra-abdominal disease. An extra-ana-
tomic liver resection, however, will not have a much higher
morbidity than a RFA during laparotomy. Is it ethical to
assign patients to open RFA as the first choice treatment?
Do we really need to compare both modalities and study
long-term survival in this particular patient group, or should
we reserve RFA for patients unable to tolerate surgery?
If there is a favorable effect of RFA on long-term sur-
vival, the biochemical and genetic background should be
first established. Identification of factors predicting the
outcome by genomic and proteomic analyses may help to
differentiate between patients who should be managed most
aggressively and those who may benefit from minimal
invasive techniques. In Rotterdam, we are currently per-
forming such a prospective controlled study including more
than 1000 patients with colorectal cancer.
Until then, the use of RFA as a treatment modality for
resectable CRLM should be restricted to high-volume,
experienced hepatobiliary centers with a multidisciplinary
approach. In the era of evidence-based medicine, we
emphasize the need for proper prospective data collection
and advocate standardized treatment and imaging algo-
rithms to justify the experimental use of RFA when applied
instead of, or in addition to, hepatic resection.
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